Clinical and laboratory assessments: At each visit a physical examination, vital signs, weight, ECOG performance status and review of adverse events is undertaken. Full blood count, biochemical profile, thyroid function and coagulation profile is performed at each visit during the treatment phase.

Tumour evaluation: Screening CT and whole body bone scan should be completed within 35 days prior to study registration. Clinical and radiological tumour assessments will be performed by CT scan (or MRI as required) at 3 monthly intervals until 24 months post SABR treatment or if evidence of clinical progression.

Biological Evaluations: Whole blood samples for immune endpoints are collected prior to SABR, first dose of pembrolizumab, at cycle 2, 4 and 8 of pembrolizumab, at disease progression (if this occurs) and at 9 and 12 months post SABR treatment. Blood plasma samples for determination of circulating plasma tumour DNA and/or cytokines will be taken before the administration of every pembrolizumab treatmen, and at 9, 12 and 24 months after end of SABR treatment at the time of imaging assessments. Tumour blocks from prior resections or biopsies of metastatic sites will be submitted. A request for newly obtained specimen (obtained up to 5 weeks prior to initiation of treatment) will be made, however, participation for this biopsy is optional. If feasible, an optional biopsy of a treated metastatic site will be performed at 9 months post completion of SABR and, in the event of disease progression, a sample from the metastatic site is also requested.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.